Trends in RCC Incidence

Now Viewing

EP: 1.Trends in RCC Incidence

EP: 2.RCC Histologies

EP: 3.Risk Models and Prognostic Factors

EP: 4.Metastatic RCC: Prognosis and Recent Advances in Care

EP: 5.Biomarker Testing in RCC: Current Approaches

EP: 6.Biomarker Testing: Methodologies, Sample Types, and Emerging Data

EP: 7.Prognostic Value of Biomarkers in RCC

EP: 8.The Role of Genetic Mutations in Prognosis and Decision-Making

EP: 9.Comparison of Older First-Line, Single-Agent Therapies

EP: 10.Newer First-Line Combination Therapy Options

EP: 11.Evolution of Combination Therapy As The Standard of Care

EP: 12.Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens

EP: 13.Safety and Efficacy Data: The CheckMate 214 Trial

EP: 14.Safety and Efficacy Data: The JAVELIN Renal 101 Trial

EP: 15.Safety and Efficacy Data: The KEYNOTE-426 Trial

EP: 16.Safety and Efficacy Data: The CheckMate 9ER Trial

EP: 17.Safety and Efficacy Data: The CLEAR Trial

EP: 18.Common Adverse Events with Single-Agent or Combination Therapy

EP: 19.Balancing Treatment Efficacy with Toxicity in Metastatic RCC

EP: 20.Strategies for Prevention and Management of Adverse Events

EP: 21.Patient-Specific Factors Impacting Treatment Choices in RCC

EP: 22.Considerations for Patient-Focused, Shared Decision-Making in RCC

EP: 23.Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer

EP: 24.The Importance of Team-Based Management and Patient Communication

EP: 25.OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC

EP: 26.Reflections on Novel Targets and Emerging Regimens for RCC

EP: 27.Clinical Pearls on Recent Advances and the Future of Treatment in RCC

EP: 28.Recap: Safety and Efficacy of Available Treatment Options and Considerations for Management of RCC

Matthew Fowler: Hello, and welcome to this Contemporary CancerNetwork® OncView™ program titled "Metastatic Renal Cell Carcinoma: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management." I'm Matthew Fowler, associate editor with CancerNetwork®. We have with us today Dr David Aggen, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City. Thank you for joining us today, Dr Aggen. Let's get started.

David Aggen, MD, PhD: Thanks for that kind intro, Matt. Happy to speak with you today.

Matthew Fowler: Our first segment focuses on a background of RCC [renal cell carcinoma], so let's set that up. Could you comment on just general RCC incidents; is it increasing, decreasing? Do you have any thoughts on the reasons behind a change that you see?

David Aggen, MD, PhD: Certainly. I think over the past several decades, we've seen a steady increase in the incidents of kidney cancer. In part, that's because our imaging modalities have improved, and as we've started to do CT scans for other reasons, we're incidentally finding small kidney masses. I think that has led to a general trend towards an increase in the number of cases of kidney cancer that we're seeing. We're catching the disease in an earlier state. I also think that there's been an improvement in our diagnostic ability in terms of catching these cancers earlier on and that's sort of led to earlier recognition of this disease entity.

Transcript edited for clarity.